100873-41-4

Basic information

• Product Name: 4-Piperidinone, 1-(3-phenoxypropyl)-
• CAS NO: 100873-41-4
• Molecular Formula: C14H19NO2
• Molecular Weight: 233.31
• Mol File: 100873-41-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-Piperidinone, 1-(3-phenoxypropyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinone, 1-(3-phenoxypropyl)-(100873-41-4)
• EPA Substance Registry System: 4-Piperidinone, 1-(3-phenoxypropyl)-(100873-41-4)

Safety Data

• Hazardous Substances Data: 100873-41-4(Hazardous Substances Data)

Upstream product

• 41979-39-9 4-piperidone hydrochloride 
• 588-63-6 3-phenoxypropyl bromide 
• 40064-34-4 4-piperidone monohydrochloride monohydrate 
• 101867-50-9 3,3'-(3-phenoxy-propylimino)-di-propionic acid dimethyl ester 

Downstream Products

• 1204739-69-4 2-(2,4-difluorophenyl)-3-[1-(3-phenoxypropyl)piperidin-4-ylideneamino]-1-(1H-1,2,4-trazol-1-yl)propan-2-ol 

Relevant articles and documents

LSD1 Inhibitors

The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.